CEL001
/ Guangzhou Xiling Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 31, 2026
A Phase I Clinical Study Evaluating the Safety and Tolerability of CEL001 Injection in the Treatment of Advanced Solid Tumors
(ChiCTR)
- P1 | N=10 | Recruiting | Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Guangzhou Celling Biological Technology Co., Ltd.
New P1 trial • Colorectal Cancer • Esophageal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ALK • BRAF • EGFR • FGFR2 • MSI • ROS1 • TMB
1 to 1
Of
1
Go to page
1